Mineralys Therapeutics, Inc. (MLYS)
15.33
+0.09
(+0.59%)
USD |
NASDAQ |
Nov 06, 16:00
15.34
+0.01
(+0.07%)
After-Hours: 20:00
Mineralys Therapeutics Enterprise Value : 830.77M for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 830.77M |
| November 05, 2026 | 822.80M |
| November 04, 2026 | 978.62M |
| November 03, 2026 | 889.20M |
| November 02, 2026 | 850.25M |
| October 30, 2026 | 1.083B |
| October 29, 2026 | 1.354B |
| October 28, 2026 | 1.366B |
| October 27, 2026 | 1.344B |
| October 26, 2026 | 1.294B |
| October 23, 2026 | 1.293B |
| October 22, 2026 | 1.374B |
| October 21, 2026 | 1.342B |
| October 20, 2026 | 1.384B |
| October 19, 2026 | 1.326B |
| October 16, 2026 | 1.271B |
| October 15, 2026 | 1.389B |
| October 14, 2026 | 1.311B |
| October 13, 2026 | 1.333B |
| October 12, 2026 | 1.442B |
| October 09, 2026 | 1.543B |
| October 08, 2026 | 1.455B |
| October 07, 2026 | 1.429B |
| October 06, 2026 | 1.417B |
| October 05, 2026 | 1.536B |
| Date | Value |
|---|---|
| October 02, 2026 | 1.566B |
| October 01, 2026 | 1.574B |
| September 30, 2026 | 1.698B |
| September 29, 2026 | 1.599B |
| September 28, 2026 | 1.701B |
| September 25, 2026 | 1.721B |
| September 24, 2026 | 1.785B |
| September 23, 2026 | 1.812B |
| September 22, 2026 | 2.034B |
| September 21, 2026 | 1.937B |
| September 18, 2026 | 1.912B |
| September 17, 2026 | 1.908B |
| September 16, 2026 | 1.869B |
| September 15, 2026 | 1.990B |
| September 14, 2026 | 1.994B |
| September 11, 2026 | 1.928B |
| September 10, 2026 | 2.025B |
| September 09, 2026 | 2.131B |
| September 08, 2026 | 2.186B |
| September 04, 2026 | 1.929B |
| September 03, 2026 | 1.934B |
| September 02, 2026 | 2.002B |
| September 01, 2026 | 1.695B |
| August 31, 2026 | 1.704B |
| August 28, 2026 | 1.698B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.983B |
| Oncolytics Biotech, Inc. | 51.10M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.085B |
| Anixa Biosciences, Inc. | 94.85M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -57.33M |
| Total Expenses (Quarterly) | 57.33M |
| EPS Diluted (Quarterly) | -0.6442 |
| Earnings Yield | -28.47% |
| Normalized Earnings Yield | -28.47 |